Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates. With a median ...
Investing.com -- Dyne Therapeutics (NASDAQ:DYN) stock rose 7% after the clinical-stage company announced positive topline results from its Phase 1/2 DELIVER trial of Z-Rostudirsen in Duchenne Muscular ...
Abstract: The requirement for precision in underwater navigation has driven the development of advanced remotely operated vehicle (ROV) systems, necessitating the integration of multiple sensors to ...
Abstract: Polypharmacy is a common means of clinical treatments, but detecting drug-drug interactions (DDIs) behind unexpected effects can be costly and faces clinical limitations. Recently, graph ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback